Rhumbline Advisers Sells 15,095 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Rhumbline Advisers lessened its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 16.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 77,084 shares of the biopharmaceutical company’s stock after selling 15,095 shares during the period. Rhumbline Advisers owned 0.16% of Theravance Biopharma worth $654,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Jacobs Levy Equity Management Inc. boosted its position in shares of Theravance Biopharma by 41.6% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 557,971 shares of the biopharmaceutical company’s stock worth $5,005,000 after purchasing an additional 163,951 shares in the last quarter. Kennedy Capital Management LLC grew its stake in shares of Theravance Biopharma by 3.7% in the first quarter. Kennedy Capital Management LLC now owns 38,202 shares of the biopharmaceutical company’s stock worth $343,000 after acquiring an additional 1,359 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Theravance Biopharma by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 49,475 shares of the biopharmaceutical company’s stock valued at $444,000 after acquiring an additional 3,532 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in Theravance Biopharma by 28.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 4,990 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its position in Theravance Biopharma by 55.7% during the 1st quarter. Russell Investments Group Ltd. now owns 45,114 shares of the biopharmaceutical company’s stock valued at $405,000 after purchasing an additional 16,135 shares during the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Stock Up 1.0 %

NASDAQ TBPH opened at $8.02 on Wednesday. The company has a 50-day moving average price of $8.62 and a 200-day moving average price of $8.85. The firm has a market capitalization of $390.04 million, a P/E ratio of -9.33 and a beta of 0.24. Theravance Biopharma, Inc. has a 52 week low of $7.44 and a 52 week high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.25). The business had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $15.81 million. Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. During the same quarter in the prior year, the business earned ($0.28) EPS. As a group, equities research analysts anticipate that Theravance Biopharma, Inc. will post -1.04 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. StockNews.com lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Theravance Biopharma in a research note on Monday, September 16th. Leerink Partnrs downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. Leerink Partners lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $15.00 to $10.00 in a research report on Tuesday, August 6th. Finally, TD Cowen dropped their price target on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Theravance Biopharma has a consensus rating of “Hold” and an average target price of $13.75.

Insiders Place Their Bets

In related news, major shareholder Eli Samaha acquired 999,800 shares of the stock in a transaction dated Wednesday, August 7th. The shares were purchased at an average cost of $7.80 per share, with a total value of $7,798,440.00. Following the transaction, the insider now directly owns 9,511,150 shares in the company, valued at $74,186,970. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Theravance Biopharma news, major shareholder Eli Samaha purchased 999,800 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were acquired at an average cost of $7.80 per share, with a total value of $7,798,440.00. Following the completion of the acquisition, the insider now directly owns 9,511,150 shares in the company, valued at $74,186,970. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now directly owns 335,965 shares of the company’s stock, valued at $3,023,685. The disclosure for this sale can be found here. Company insiders own 6.90% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.